Hamilton EP, Patel MR, Borges VF, Meisel JL, et al. Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results. Breast Cancer Res 2025;27:119.
PMID: 40598566